Amarin Presents New REDUCE-It Data at American College of Cardiology

Findings on eicosapentaenoic acid's potential multifactorial biologic activities shared at annual conference

Mar. 16, 2026 at 9:07pm

Got story updates? Submit your updates here. ›

Amarin Corporation plc presented additional REDUCE-IT patient subgroup analysis and mechanistic data on the potential multifactorial biologic activities of eicosapentaenoic acid at the American College of Cardiology's Annual Scientific Session & Expo in New Orleans. The featured Amarin-supported abstracts included an oral presentation on the efficacy of Icosapent Ethyl among patients at extreme cardiovascular risk, and a poster presentation on the rates of lipoprotein(a) oxidation and inhibition by eicosapentaenoic acid.

Why it matters

The REDUCE-IT study evaluated the effect of Amarin's VASCEPA (icosapent ethyl) in adult patients with LDL-C controlled by statin therapy but persistent elevated triglycerides, a population at high risk for cardiovascular events. The new data provides additional insights into VASCEPA's potential benefits for high-risk patients.

The details

REDUCE-IT was a global cardiovascular outcomes study that followed 8,179 patients over seven years, evaluating the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL. The primary results of REDUCE-IT were published in The New England Journal of Medicine in 2018, and the total events results were published in the Journal of the American College of Cardiology in 2019.

  • REDUCE-IT was completed in 2018.
  • The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.
  • The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.
  • VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy.
  • In Europe, marketing authorization for VAZKEPA (the brand name for icosapent ethyl in the EU) was granted in March 2021 for the reduction of risk of cardiovascular events in patients at high cardiovascular risk.

The players

Amarin Corporation plc

A pharmaceutical company that developed VASCEPA (icosapent ethyl), the first prescription treatment approved by the U.S. FDA comprised solely of the active ingredient eicosapentaenoic acid.

REDUCE-IT

A global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled by statin therapy but persistent elevated triglycerides.

VASCEPA

The brand name for Amarin's prescription treatment comprised solely of the active ingredient icosapent ethyl, a unique form of eicosapentaenoic acid.

VAZKEPA

The brand name for icosapent ethyl in the European Union, approved for the reduction of risk of cardiovascular events in patients at high cardiovascular risk.

Got photos? Submit your photos here. ›

The takeaway

The new data presented by Amarin at the American College of Cardiology conference provides additional evidence supporting the potential cardiovascular benefits of VASCEPA (icosapent ethyl) for high-risk patients, building on the positive results from the landmark REDUCE-IT study.